Compare Sea Limited (SE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sea Limited trades at $94.06 (market cap $58.38B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Sea Limited is far larger — about 7.9× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sea Limited for 103 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SE | SYRE | |
|---|---|---|
Market Cap | $58.38B | $7.35B |
Volume | 3,918,232 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $165.70 | $108.92 |
52-Week Low | $78.16 | $22.18 |
Typical Hold Time | 103 Days | 0 Days |
Enterprise Value | $53.40B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $95.93, showing minimal daily movement with a 0.05% gain. The stock faces bearish technical signals but maintains strong fundamental growth with revenue increasing from $12.4B in 2022 to $22.9B in 2025. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. Analyst sentiment remains overwhelmingly positive with 72.7% buy ratings and a $153.67 consensus price target representing 60% upside potential.
Sea's investment case hinges on continued e-commerce and fintech expansion, though recent insider selling and competitive pressures pose risks. The company's improving profitability trajectory and strong cash flow generation support long-term growth prospects, but investors should monitor execution on Shopee's margin improvement and Garena's gaming segment stability amid market volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
